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arotid Artery Stent Placement
hristopher J. White, MD
ew Orleans, Louisiana
n the past 3 years, there have been signiﬁcant developments in the ﬁeld of carotid revascularization,
ncluding: 1) the results of a large primary stroke prevention trial; 2) the emergence of novel platforms
or emboli protection; 3) improved characterization of the high-risk carotid artery stent (CAS) patient;
) completion of several very large post-market surveillance (PMS) trials of CAS in high-surgical-risk
atients; and 5) the completion of 4 large randomized controlled trials comparing CAS with carotid
ndarterectomy in average-risk patients. The purpose of this review is to update the current status of
evascularization therapies to reduce stroke in patients with extracranial carotid artery disease with a
ocus on the most recent developments regarding the role of CAS. (J Am Coll Cardiol Intv 2010;3:
67–74) © 2010 by the American College of Cardiology Foundationm
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Ctroke Prevalence, Demographic Data,
nd Etiology
he third leading cause of death in the U.S. is
troke, with more than three-quarter of a million
trokes/year. Stroke is a leading cause of functional
mpairment in adults, with approximately 20% of
urvivors requiring institutional care and up to
ne-third having a permanent disability (1). More
orrisome, however, is that as the population ages
he numbers of patients suffering strokes seem to
e increasing (2).
Most strokes are ischemic and are caused by
therosclerotic emboli from the carotid artery or
he aortic arch, or they are related to thromboem-
olism from the heart chambers. The incidence of
symptomatic extracranial carotid stenosis (50%)
n persons 65 years of age is estimated to be
etween 5% and 10%, with fewer than 1% having
critical stenosis (80%) (3). The annual risk of
troke is between 1% and 4.3% for asymptomatic
atients with 50% stenosis of the carotid artery
4,5). The asymptomatic patients at highest risk of
troke are those with severe stenoses or those with
rogressive carotid narrowing (3,4). Unfortunately,
rom The John Ochsner Cardiovascular Institute, New Orleans,
ouisiana. Dr. White is the Principal Investigator for the CABANA
rial sponsored by Boston Scientific Corp.tanuscript received April 5, 2010, accepted April 7, 2010.ost (approximately 80%) strokes have no warning
ymptoms. Therefore, identifying asymptomatic
atients at high risk is important (4,6,7).
The risk of atheroembolic stroke is directly
elated to the severity of carotid artery stenosis and
he presence of symptoms (4,8). Symptomatic
atients have a worse prognosis compared with
symptomatic patients. A transient ischemic attack
TIA), defined in the past as a neurologic event
asting 24 h, predicted a 15% risk of stroke at 1
onth and a 30% risk of TIA, stroke, or death
ithin 3 months (9,10). The risk of ipsilateral
troke in symptomatic patients on medical therapy
ncreases with the severity of the stenosis. In the
ASCET (North American Symptomatic Carotid
ndarterectomy Trial) the stroke rate was 22%
mong those with moderate (50% to 69%) stenosis
nd 26% with a 70% to 99% carotid stenosis (11).
he very tightest lesions, near occlusions, defined
n the ECST trial (European Carotid Surgery
rial) as a severe stenosis with evidence of reduced
ow in the distal carotid artery and evidence of
arrowing of the post-stenotic carotid artery, pa-
ients did not benefit from carotid endarterectomy
CEA) (12,13).
EA
EA versus medical therapy. Carotid endarterec-
omy has been established in the late 20th century
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468s the preferred treatment to prevent stroke for usual or
verage-surgical-risk symptomatic patients with 50% ca-
otid stenosis (13–15) and average-risk asymptomatic pa-
ients with 60% carotid stenosis (16–18) compared with
edical therapy. Primary prevention has consisted of pri-
arily blood pressure control, tobacco cessation, and aspirin
herapy, but recently the JUPITER (Justification for the Use
f statins in Prevention: an Intervention Trial Evaluating
osuvastatin) trial demonstrated significant risk reduction
or stroke with statins (19). Several other lipid-lowering
rials, in patients at increased risk for stroke due to cardio-
ascular disease, have also shown efficacy for statin therapy
o reduce stroke (20–23). The comparative benefit of CEA
n patients treated with modern antiatherosclerotic therapy
as not been established.
EA procedure risk. The clinical benefit of CEA must be
alanced against the perioperative risk associated with the
procedure. An expert consensus
panel suggested that CEA was
beneficial if the perioperative risk
of stroke and death did not exceed
3% for asymptomatic patients and
6% for symptomatic patients
(24,25). However, increased risk
of perioperative stroke and death
rates have been reported for repeat
CEAs (10.9%) (26) and in pa-
tients with contralateral carotid
occlusions (14.3%) (27). There is
consensus among experts that
there is a population of patients
who are at increased risk of com-
plications with CEA due to a
variety of unfavorable anatomical
features and/or medical comor-
bidities (Table 1) (28–36).
arotid Artery Stenting (CAS)
AS procedure risk. There is little overlap among risk factors
r patient characteristics that increase the peri-procedural risk
fter CAS or CEAwith a few notable exceptions (Tables 1 and
). Some are supported by clinical evidence (37–49), such as
he finding that echolucent plaques are associated with a higher
vent rate with CAS (38), whereas others are based upon
xpert consensus (50,51).
The risk for a CAS complication increases with anything
hat prolongs catheter/guidewire manipulation in the aortic
rch, makes lesion crossing more difficult, decreases the
uccessful deployment or retrieval of an embolic protection
evice (EPD), or makes stent placement difficult (51). The
ost difficult anatomic features for CAS were a complex
ortic (Type III) arch, circumferential lesion calcification,
bbreviations
nd Acronyms
AS  carotid artery
tenting
EA  carotid
ndarterectomy
I  confidence interval
WI  diffusion weighted
maging
PD  embolic protection
evice
DA  Food and Drug
dministration
I  myocardial infarction
EO  proximal embolic
cclusion
IA  transient ischemic
ttackevere angulation of the internal carotid artery, severetherosclerotic disease of the aortic arch, and a tortuous
ommon carotid artery. Other features that might increase
he risk of CAS include patients with dementia due to
ultiple lacunar strokes, cerebral microangiopathy with
iminished vascular reserve, increased risk of bleeding or
oagulation disorders, difficult vascular access, and kidney
isease (50).
An increased complication rate for CAS in elderly pa-
ients (75 to 80 years of age) has been clearly demon-
trated (Table 3) (37,39,43,52). Younger (69 years of age)
atients have been shown to have lower event rates with
AS compared with CEA in 2 large randomized trials
45,53). Elderly patients (80 years of age) are more likely
o have tortuous vessels, unfavorable aortic arches, and more
omplex carotid lesions (44). Despite these facts, it has been
learly shown by several groups that, with experience and
areful patient selection, excellent CAS outcomes are at-
ainable even in very elderly persons (Fig. 1) (54–57).
The experience of CAS operators and hospital volumes
as a direct impact on procedure outcomes (58–60). The
ead-in patients for the CREST (Carotid Revascularization
ndarterectomy and Stenting Trial) demonstrated that
atheter-based subspecialties (Radiology and Cardiology)
xperienced one-half the number of complications as the
ascular surgeons, which was statistically significant (Fig. 2)
61). After successful completion of lead-in cases, which
nsured operator competence, the final CREST results
Table 1. Features That Increase Risk of CEA
Anatomic Criteria Medical Comorbidity
High cervical or intrathoracic lesion Age 80 yrs
Prior radical neck surgery or radiation Class III/IV congestive heart failure
Contralateral carotid artery occlusion Class III/IV angina pectoris
Prior ipsilateral CEA Left main coronary disease
Contralateral laryngeal nerve palsy Multivessel coronary artery disease
Tracheostoma Urgent (30-day) heart surgery
LV ejection fraction 30%
Recent (30-day) myocardial infarction
Severe lung disease
Severe renal disease
CEA carotid endarterectomy; LV left ventricular.
Table 2. Features That Increase Risk of CEA
Comorbidities Anatomic Features Procedural Factors
Age 80 yrs Complex aortic arch Operator inexperience
Symptomatic Tortuosity No emboli protection device
Decreased cerebral
reserve
Calciﬁcation Time delay from symptom
onset
Hypercoagulable state Intraluminal thrombus Open cell stents
Severe renal disease Echolucent plaque Vascular access difﬁculty
Increased bleeding riskCEA carotid endarterectomy.
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469eported that the quality gap for the vascular surgeons had
een closed (53). Three European trials (EVA-3S [Endar-
erectomy versus Angioplasty in Patients with Symptomatic
evere Carotid Stenosis] [62], SPACE [Stent-Supported
ercutaneous Angioplasty of the Carotid Artery versus
ndarterectomy] [63], and the ICSS [International Carotid
tenting Study] [64]) allowed very inexperienced CAS
nvestigators (39% of the CAS operators were actually
rainees) to enroll patients, which might have biased the
utcomes of those trials (65).
Although EPD use with CAS has never been subjected
o a randomized controlled trial, most experienced operators
elieve that embolic protection is necessary with CAS, the
.S. Food and Drug Administration (FDA) approved the
evices without randomized evidence, and Medicare will
ot reimburse for a CAS procedure in which an EPD has
ot been used. A meta-analysis of 4,747 patients in 24 CAS
tudies found a significant benefit for protected procedures
ith a relative risk reduction of 0.59 (95% confidence
nterval [CI]: 0.47 to 0.73) (49). New brain lesions detected
Table 3. Increased Risk of CAS With Very Elderly Patients
Trial
Roubin et al.
(52)
CREST Lead-In
(37)
CAPTURE
(43)
BEACH
(39)
80 yrs of age 6% 2.8% 5.6% 3.4%*
80 yrs of age 16% 12.1% 8.1% 9.1%†
p value 0.01 0.01 0.05 0.002
*75 years of age; †75 years of age.
BEACH Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-
Risk Surgical Patients; CAPTURE  Carotid ACCULINK/ACCUNET Post Approval Trial to
Uncover Rare Events; CAS  carotid artery stenting; CREST  Carotid Revascularization
Endarterectomy and Stenting Trial.
Figure 1. Carotid Artery Stenting With Favorable Outcomes in Very
Elderly Patientsi
Created from data published in Grant et al. (57).y magnetic resonance diffusion weighted imaging (DWI)
orrelate with complex aortic arch vessels, more contrast
sage, and longer fluoroscopic times during diagnostic
erebral angiography (47,66). The appearance of new con-
ralateral hemisphere DWI lesions is compelling evidence
hat some cerebral emboli are caused by catheter manipu-
ation in the aortic arch and explains why 20% of all strokes
ssociated with CAS affect the contralateral hemisphere
67,68). Quantitatively, fewer transcranial Doppler embolic
ignals and fewer DWI brain lesions occur with an EPD in
lace compared with no EPD used with CAS (69,70).
hen comparing a distal balloon occlusion EPD with a
lter EPD during CAS, no difference was found between
he devices with new cerebral lesions detected in 40% of
oth groups (71); however, transcranial Doppler has shown
ewer embolic signals with a proximal embolic occlusion
PEO) device compared with a filter EPD (72).
There is continuing debate regarding the stent type (open
ell vs. closed cell) on the occurrence of CAS complications.
pen cell stents are typically more flexible and conformable
n tortuous lesions, whereas closed cells stents offer better
esion coverage. Several authors have observed an increase in
AS complication rates with open cell stents (73), partic-
larly in symptomatic patients (40) and those with echolu-
ent plaques (74). Complications in these symptomatic
atients correlate with the “free cell area” of the stents (40).
owever, a large CAS series failed to show any relationship
f stent type with CAS complications (75), with the authors
ointing out that, without a randomized control trial, lesion
orphology—which drives stent choice—might confound
he observed outcomes. For example, open cell stents are
referred in more complex angulated lesions, which are
ore likely to cause complications, whereas closed cell
tents are preferred in straighter lesion segments, introduc-
Figure 2. Data Demonstrating Differences in Operator Outcomes by
Specialty for CREST Lead-In Trial
Created from data published in Hopkins et al. (61). CI  conﬁdence inter-
val; CREST  Carotid Revascularization Endarterectomy and Stenting Trial;
INR  international neuroradiologists; IR  interventional radiology; OR 
odds ratio.ng a bias in favor of closed cell stents (75).
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470Earlier intervention (14 days) after a symptomatic event
as become recommended therapy for CEA, given the high
ecurrent event rate for symptomatic patients (25). It is
nclear whether the timing of CAS after a symptomatic
vent is beneficial or carries an increased risk of complica-
ions. In the symptomatic (stroke or TIA) subset of the
ulticenter CAPTURE (Carotid ACCULINK/ACCUNET
ost Approval Trial to Uncover Rare Events) (n  482),
here was an increase in complications associated with CAS
erformed within 2 weeks of the symptomatic event (p 
.0047; odds ratio: 2.52, 95% CI: 1.33 to 4.78) (43).
owever, in 320 symptomatic CAS patients treated at 2
igh-volume European centers, early intervention (14 days
rom onset of symptoms) with CAS was not associated with
ncreased complications (46). Clarification of the risk/benefit
atio for early CAS intervention in symptomatic patients with
AS will require better-controlled clinical trials.
eporting bias. In a systematic analysis of all published
eports of CEA since 1980, there was significant heteroge-
eity in the reporting of surgical complications that varied
ccording to the specialty of the authors (76). The compli-
ation rate was highest in studies including an independent
eurologist for post-operative assessment. In contrast, the
owest complication rates were reported in studies authored
y a single surgeon. Inconsistent definitions, a lack of
ndependent neurological assessment, diverse specialty par-
icipation, and highly variable case selection make compar-
sons among centers, techniques, and outcomes unreliable.
One cannot expect to meaningfully compare outcomes of
AS and CEA when the CAS group is held to a higher
eporting standard than for CEA. The group with indepen-
ent neurological examination (CAS) will always have a
igher rate of complications than the routine clinical care
roup (CEA). The majority of CAS procedures performed
n the U.S. in 2005 were performed in high-surgical-risk
atients, under an FDA-sponsored protocol with a required
xamination by a neurologist. The vast majority of CEAs
erformed in 2005 were not performed in a clinical trial
nvironment and had no independent neurological assess-
ent, in contrast to the diligent oversight required for CAS
rocedures. Despite general awareness of this ascertainment
ias, several publications have compared CEA and CAS,
elying on databases that systematically under-report CEA
omplications (77–79). This ascertainment bias strongly
avors CEA when compared with CAS, which leads to
nappropriate comparisons of the 2 techniques (76,80,81).
AS for high-surgical-risk patients. The SAPPHIRE
Stenting and Angioplasty with Protection in Patients at
igh risk for Endarterectomy) trial is the only randomized
ulticenter trial comparing CEA and CAS in patients at
ncreased risk for surgery (Table 1) (82). Important to the
alidity of this trial, vis a vis the European CAS trials that
ermitted very inexperienced CAS operators to treat pa-
ients, was the parity of the experienced CAS and CEAnvestigators. The surgeons had a median annual volume of
0 CEAs (range 15 to 100), and interventionalists had a
edian experience of 64 CAS procedures (range 20 to 700).
t 1 year, the primary end point for the CEA group was
0.1%, and for CAS it was 12.2% (adjusted relative risk:
.9%, 95% CI: 16.4% to 0.7%, p  0.004 for noninferior-
ty). With a per protocol analysis, for the 310 patients who
eceived their assigned treatment, the primary end point at
-year for CEA was 20.1% and for CAS was 12.0%
p  0.048) (82) After 3 years of follow-up, there were no
ifferences between the groups (Fig. 3) (83,84).
After FDA approval, the SAPPHIRE trial was continued
s a post-market surveillance registry of CAS (SAPPHIRE
orld-Wide) and reported 4.0% 30-day stroke and death
n 2,001 high-surgical-risk patients (anatomic  716, co-
orbid 918, and both 327) (Fig. 4) (85). The EXACT
rial (Emboshield and Xact Post Approval Carotid Stent
rial) enrolled 2,145 patients, and the CAPTURE-2 trial
nrolled 4,175 patients. For comparable patients, relative to
he 2006 American Heart Association published guidelines
25) (80 years), their results for CAS exceeded the recom-
ended 30-day stroke and death rate thresholds for both
ymptomatic patients (50% stenosis) at 5.3% and asymptom-
tic patients (80% stenosis) at 2.9% (Fig. 4) (67).
AS for usual-surgical-risk patients. Four large randomized
ontrolled trials have recently compared CAS with CEA in
sual- or average-surgical-risk patients (Table 4). Three of
he trials (SPACE [63], EVA-3S [86], and ICSS [64])
ere European, whereas the largest trial, CREST (53), was
ased in the U.S. and Canada. The European trials enrolled
nly symptomatic patients and required far less CAS expe-
ience compared with CEA experience. They allowed CAS
rial procedures to be done by inexperienced operators
trainees) and a proctor. Embolic protection was optional in
he European trials. The CREST trial only allowed quali-
Figure 3. 3-Year Outcomes for Randomized SAPPHIRE Trial
Reproduced with permission from Gurm et al. (83). SAPPHIRE  Stenting
and Angioplasty with Protection in Patients at High risk for
Endarterectomy.
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471ed operators to participate in carotid stenting and man-
ated the use of an EPD.
The EVA-3S (62) trial is a clear outlier among these
rials. It was stopped early for safety concerns with a
uperior 30-day stroke and death outcome for CEA (3.9%)
ompared with CAS (9.6%, p  0.004). The EVA-3S trial
llowed very inexperienced CAS operators to be tutored
hile enrolling in the trial, the use of EPDs was optional,
nd 13 CAS procedures were converted to CEA during the
rocedure, which is a quality of care “red flag.” For patients
ot treated with an EPD, the stroke and death rate was
-fold higher than those treated with an EPD.
The SPACE (63) trial included 1,200 symptomatic
atients randomized to CEA or CAS. Again, the CAS
perators were inexperienced compared with the surgical op-
rators (Table 4). However, the 30-day stroke and death rate
as not different between the groups with CAS at 6.84% and
Figure 4. CAS Outcome Data for High-Surgical-Risk Patients From Large
Post-Market Surveillance Trials
Created from data published in Gray et al. (67). CAPTURE 2  Carotid
ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events; CAS 
carotid artery stenting; EXACT  Emboshield and Xact Post Approval
Carotid Stent Trial; SAPPHIRE  Stenting and Angioplasty with Protection
in Patients at High risk for Endarterectomy.
Table 4. CAS Versus CEA in Average-Surgical-Risk Patients
30-Day Stroke & Death
Symptomatic (%)CEA (%) CAS (%)
SPACE (63) 6.3 6.8 100
EVA-3S (86) 3.9 9.6† 100
ICSS (64) 4.0 7.4† 100
CREST (53) 4.5 5.2 53
The ICSS (International Carotid Stenting Study) and CREST 30-day outcomes include periprocedural
results by committee before allowing enrollment.
EPD  emboli protection device; Sx  symptomatic; EVA-3S  Endarterectomy versus AngioAngioplasty of the Carotid Artery versus Endarterectomy; other abbreviations as in Tables 1 and 3.EA at 6.34% (p  NS). After 2 years of follow-up there
ontinued to be no differences between the CEA or CAS
roups; however, patients 68 years had a statistically signif-
cant better outcome with CAS compared with CEA.
The recent publication of the multicenter ICSS trial (64)
uggested no difference for the primary end point of
isabling stroke or death (CAS 4.0% vs. CEA 3.2%,
 0.34). For this interim report they did find an excess of
inor strokes (Rankin score3 and/or resolved by 30 days)
n the CAS group. Once again, there was a significant
mbalance in the experience level of the investigators per-
orming CEA compared with those performing CAS (Ta-
le 4). Investigators were permitted to enroll patients while
eing tutored in the procedure, and EPDs were not re-
uired. Two inexperienced sites produced 5 of the total 17
ajor strokes observed in the trial while treating only 11
atients. These terrible results are reminiscent of the “stopped
rial” reported from Britain by Naylor et al. (87), in which
ovice CAS operators wreaked havoc among the CAS group,
ausing strokes in 70% of their patients. The ethical issues
elated to allowing very inexperienced operators to perform
AS in a clinical trial setting, perhaps to accelerate lagging
nrollment, has been emphasized by Roffi et al. (88).
The CREST trial, the largest multicenter randomized
ontrolled trial of CAS versus CEA trials, has recently been
ompleted (53). The CREST trial enrolled 2,502 average-
urgical-risk, symptomatic (53%) and asymptomatic (47%)
atients. There was no difference between CAS and CEA
or the primary end point (any stroke, myocardial infarction
MI], or death with the peri-procedural period, plus any
psilateral stroke thereafter). Patients were followed out to 4
ears without any difference between CAS (7.2%) or CEA
6.8%) with a hazard ratio of 1.11 (95% CI: 0.81 to 1.51;
 0.51). There was an excess of strokes with CAS (4.1%)
ompared with CEA (2.3%), but the majority of these were
inor strokes, because there was no difference for major
trokes (CAS 0.9% vs. CEA 0.7%). The CEA group had twice
s many MIs (2.3%) compared with CAS (1.1%). Cranial
erve palsy occurred in 4.8% of the CEA patients. There was
imum Experience CEA (n) Minimum Experience CAS EPD Use
25 10* Optional
25 5* Optional
50 10* Optional
50 20‡ Required
toring for CAS during enrollment of trial patients allowed; †p 0.01; ‡cases reviewed for outcome
n Patients with Symptomatic Severe Carotid Stenosis; SPACE  Stent-Supported PercutaneousMin
MI. *Tu
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472n age effect, with younger patients (69 years of age) doing
etter with CAS, and older patients doing better with CEA.
Comparing the ICSS and CREST trials shows that for
ajor stroke and death there are no differences between
EA and CAS. Both trials revealed an excess of minor
trokes in the CAS group. The CREST trial required CAS
perators to be more experienced than the ICSS trial did.
imilar criteria for perioperative MIs were used for both
rials; however, the ICSS surgeons reported far fewer
eriprocedural MIs (0.5%) than the CREST surgeons
2.3%), demonstrating either the superiority of surgeons in
urope or a systematic under-reporting of complications by
he ICSS surgeons (53,64).
onclusions
he optimal role of carotid artery revascularization (CAS or
EA) for stroke prevention continues to be debated. The
revalence of ischemic stroke is likely improving with more
ffective medical therapy. It no longer seems reasonable to
uote best medical therapy outcomes on the basis of the aspirin
reatment arms of 20th century trials. The accumulated evi-
ence from thousands of high-surgical-risk patients, for whom
arotid revascularization was advised for stroke prevention, tells
s that CAS is the procedure of choice in a suitable patient
ho can have the procedure performed in an experienced
acility by an experienced interventionalist.
For average- or low-surgical-risk patients who are
eemed to be candidates for carotid artery revascularization,
he data suggest that, if a patient is a candidate for either
rocedure, the decision regarding the choice of CAS or
EA should be made by the patient and their physician.
learly some patients will fare better with surgical treat-
ent, whereas others will do as well or better with stenting.
he experience of the facility, support personnel, and the
hysician is extremely important in obtaining optimal out-
omes with either technique. No one would suggest that a
asual or low-volume general surgeon will achieve the same
esults as a high-volume vascular surgeon operating in a
igh-volume center with experienced nurses caring for their
EA patient. The same is true, perhaps more true for CAS,
iven the rapid evolution of technique. One of the biggest
dvantages of experience and volume is the knowledge of
hich patients are not candidates for CAS.
The most interesting blip on the CAS horizon is the
mergence of PEO devices. The earliest versions of these
evices were cumbersome, difficult to use, and not widely
dopted. But as PEO devices become more user-friendly,
hey have the opportunity to dramatically reduce periproce-
ural emboli associated with CAS. A recently published
eport described 1,300 consecutive CAS procedures with
eurology oversight and reported a 30-day stroke and death
ate of only 1.4% (89). If these remarkable results are
eproducible, then the “tipping point” might have beeneached favoring CAS over CEA for all but the few patients
ho are not suitable for stenting (90).
eprint requests and correspondence: Dr. Christopher J. White,
epartment of Cardiology, The John Ochsner Heart and Vascular
nstitute, Ochsner Medical Center, 1514 Jefferson Highway, New
rleans, Louisiana 70121. E-mail: cwhite@ochsner.org.
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